- Home
- Publications
- Publication Search
- Publication Details
Title
Translating JAKs to Jakinibs
Authors
Keywords
-
Journal
JOURNAL OF IMMUNOLOGY
Volume 204, Issue 8, Pages 2011-2020
Publisher
The American Association of Immunologists
Online
2020-04-07
DOI
10.4049/jimmunol.1901477
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency
- (2020) Fahad Alsohime et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation
- (2019) Nick Zimmermann et al. JAMA Dermatology
- Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
- (2019) Andres Forero-Torres et al. BLOOD
- PF-06651600, a dual JAK3/TEC family kinase inhibitor
- (2019) Hua Xu et al. ACS Chemical Biology
- Identification of rare coding variants in TYK2 protective for rheumatoid arthritis in the Japanese population and their effects on cytokine signalling
- (2019) Tomoki Motegi et al. ANNALS OF THE RHEUMATIC DISEASES
- Targeting Interleukin-6 Signaling in Clinic
- (2019) Sujin Kang et al. IMMUNITY
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry
- (2019) Gaspard Kerner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
- (2019) Katie Bechman et al. RHEUMATOLOGY
- Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report
- (2019) Dylan Haynes et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
- (2019) Mark C. Genovese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis
- (2019) Ana B. Pavel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease
- (2019) Zhiwei Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate
- (2019) Leonard H Calabrese et al. ARTHRITIS CARE & RESEARCH
- Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial
- (2019) Roy Fleischmann et al. Arthritis & Rheumatology
- Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
- (2019) Peter C. Taylor et al. Journal of Clinical Medicine
- Recurrent somatic JAK3 mutations in NK-cell enteropathy
- (2019) Wenbin Xiao et al. BLOOD
- Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomised, double‐blind, vehicle‐controlled Phase 2a study
- (2019) M. Worm et al. BRITISH JOURNAL OF DERMATOLOGY
- Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
- (2019) Joseph L. Benci et al. CELL
- Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
- (2019) Hidemi Nakagawa et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis
- (2019) Melinda J. Gooderham et al. JAMA Dermatology
- Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
- (2018) Tycel J. Phillips et al. BLOOD
- Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
- (2018) H. Nakagawa et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
- (2018) G.J. Schmieder et al. BRITISH JOURNAL OF DERMATOLOGY
- Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials
- (2018) Madan Jagasia et al. Immunotherapy
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
- (2018) Bruce E Sands et al. Journal of Crohns & Colitis
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- (2018) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
- (2018) Kevin L. Winthrop et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
- (2018) J. Berdeja et al. LEUKEMIA RESEARCH
- Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients
- (2018) Walter P Maksymowych et al. RHEUMATOLOGY
- The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
- (2018) Douglas J Veale et al. RHEUMATOLOGY
- Momelotinib therapy for myelofibrosis: a 7-year follow-up
- (2018) Ayalew Tefferi et al. Blood Cancer Journal
- The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells
- (2018) C. Enerbäck et al. Scientific Reports
- Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase
- (2018) Stevan R. Hubbard Frontiers in Endocrinology
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
- (2018) Yoshiya Tanaka et al. Arthritis & Rheumatology
- Diagnosis and Management of Rheumatoid Arthritis
- (2018) Daniel Aletaha et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
- (2018) Hart S. Dengler et al. Science Translational Medicine
- Tofacitinib relieves symptoms of stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173
- (2017) Jieun Seo et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome
- (2017) Kate L. Del Bel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
- (2017) Atli Thorarensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fatal ruxolitinib-related JC virus meningitis
- (2017) Begoña Ballesta et al. JOURNAL OF NEUROVIROLOGY
- Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Jak3 deficiency blocks innate lymphoid cell development
- (2017) M L Robinette et al. Mucosal Immunology
- Managing rheumatic and musculoskeletal diseases — past, present and future
- (2017) Gerd R. Burmester et al. Nature Reviews Rheumatology
- Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study
- (2017) Kensuke Kume et al. RHEUMATOLOGY INTERNATIONAL
- Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis
- (2017) T Komai et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci
- (2017) Laura A. McIntosh et al. Arthritis & Rheumatology
- The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
- (2016) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
- (2016) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
- (2016) Matthew D. Blunt et al. CLINICAL CANCER RESEARCH
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173 -activating mutations in 3 children
- (2016) Marie-Louise Frémond et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection
- (2016) Davide Eletto et al. Nature Communications
- Trisomy 21 consistently activates the interferon response
- (2016) Kelly D Sullivan et al. eLife
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Molecular mechanisms of pruritus
- (2016) J. Meng et al. Current Research in Translational Medicine
- SP0027 One for All – Patient Research Partners Involved in Disseminating Eular Recommendations Among Belgium Patients
- (2015) I. De Keyser ANNALS OF THE RHEUMATIC DISEASES
- The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
- (2015) S J Thomas et al. BRITISH JOURNAL OF CANCER
- Super-enhancers delineate disease-associated regulatory nodes in T cells
- (2015) Golnaz Vahedi et al. NATURE
- Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
- (2015) G Montealegre et al. Pediatric Rheumatology
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- Editorial: Decernotinib: A Next-Generation Jakinib
- (2015) Massimo Gadina et al. Arthritis & Rheumatology
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
- (2015) Vijay U. Rao et al. Arthritis & Rheumatology
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- (2015) S. Harel et al. Science Advances
- Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis
- (2014) S. C. Meyer et al. BLOOD
- In Search of Magic Bullets: The Golden Age of Immunotherapeutics
- (2014) John J. O’Shea et al. CELL
- Selective JAK inhibitors in development for rheumatoid arthritis
- (2014) Peter Norman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Intravenous golimumab in rheumatoid arthritis
- (2014) Marc D Cohen et al. Expert Review of Clinical Immunology
- Anti-TNF therapy: past, present and future
- (2014) C. Monaco et al. INTERNATIONAL IMMUNOLOGY
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
- (2013) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
- (2013) Sung O. Park et al. PLoS One
- Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases
- (2010) Jin-Hui Tao et al. MOLECULAR BIOLOGY REPORTS
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started